AR and neoplasm: LAR cells partly depend on AR (androgen receptor) signaling, as demonstrated by the inhibition of cell viability and tumor growth when AR is targeted by bicalutamide, an AR antagonist, and are less likely to benefit from chemotherapy regimens [83].